Skip to main content

Clinical Trials Using Ramucirumab

Review the clinical trials studying ramucirumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-21 of 21

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Status: Active
Location: 446 locations
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer that has EGFR and MET Gene Changes (An Expanded Lung-MAP Treatment Trial)
Status: Active
Location: 421 locations
Adding Nivolumab to Usual Treatment for People with Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Status: Active
Location: 362 locations
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People with Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment with Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Status: Active
Location: 338 locations
Targeted Treatment for Advanced Non-Small Cell Lung Cancer that has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Status: Active
Location: 246 locations
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Status: Active
Location: 16 locations
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Status: Active
Location: 9 locations
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Status: Active
Location: 7 locations
Lorlatinib in Combination with Ramucirumab for Treatment in Patients with Advanced ALK-rearranged Advanced Non-Small Cell Lung Cancer
Status: Active
Location: 7 locations
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
Status: Active
Location: 6 locations
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Status: Active
Location: 4 locations
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Status: Active
Location: 4 locations
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
Status: Active
Location: 2 locations
Nivolumab and Ramucirumab for the Treatment of Recurrent, Advanced, or Metastatic Non-Small Cell Lung Cancer
Status: Active
Location: 2 locations
Pembrolizumab With or Without Ramucirumab for the Treatment of PD-L1 Positive, Recurrent or Metastatic Head and Neck Squamous-Cell Cancer
Status: Active
Location: 2 locations
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Carboplatin, Paclitaxel, and Ramucirumab for the Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Nab-Paclitaxel PIPAC in Combination with Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer with Peritoneal Metastases
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Volrustomig Priming Regimens Exploratory Phase II Platform Study
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
Status: Active
Location: Nationwide Children's Hospital, Columbus, Ohio
Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)
Status: Active
Location: 1106 locations